Abstract
Tolvaptan is a novel oral selective arginine vasopressin V2-receptor antagonist. Tolvaptan improves heart failure signs and symptoms without serious adverse events. Tolvaptan has no effect on all-cause mortality and cardiovascular death or admission rate for heart failure. But in heart failure patients with hyponatremia, tolvaptan can decrease cardiovascular death and admission rate for heart failure. Key words: Tolvaptan; Heart failure, congestive; Hyponatremia
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
